Spark Therapeutics (NASDAQ:ONCE) Downgraded by Zacks Investment Research to Sell

Zacks Investment Research cut shares of Spark Therapeutics (NASDAQ:ONCE) from a hold rating to a sell rating in a report released on Wednesday, Zacks.com reports.

According to Zacks, “Spark Therapeutics, Inc. offers gene therapy. The Company’s product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania. “

Separately, Mizuho restated a hold rating and set a $114.50 price objective on shares of Spark Therapeutics in a research note on Monday, August 12th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus target price of $87.92.

Shares of ONCE opened at $100.57 on Wednesday. The stock’s 50-day moving average is $99.69 and its two-hundred day moving average is $99.51. The stock has a market cap of $3.80 billion, a PE ratio of -47.66 and a beta of 2.07. Spark Therapeutics has a 12 month low of $34.53 and a 12 month high of $114.20. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.56 and a quick ratio of 5.59.

Several institutional investors and hedge funds have recently modified their holdings of the business. Sterling Investment Advisors Ltd. purchased a new stake in shares of Spark Therapeutics during the first quarter worth about $68,000. CSat Investment Advisory L.P. purchased a new stake in shares of Spark Therapeutics during the second quarter worth about $113,000. Meeder Asset Management Inc. purchased a new stake in shares of Spark Therapeutics during the first quarter worth about $121,000. Janney Montgomery Scott LLC purchased a new stake in shares of Spark Therapeutics during the second quarter worth about $202,000. Finally, Ancora Advisors LLC purchased a new stake in shares of Spark Therapeutics during the second quarter worth about $205,000. Institutional investors own 84.08% of the company’s stock.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.

Further Reading: Street Name

Get a free copy of the Zacks research report on Spark Therapeutics (ONCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.